WebFeb 12, 2024 · Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen Case Rep Hematol. 2024 Feb 12;2024:1378056. doi: 10.1155/2024/1378056. eCollection 2024. Authors WebMay 1, 2024 · We studied the 19 patients whose disease was refractory to initial induction with Ida-FLAG. Of these 19 patients, 9 (47.4%) received intensive reinduction …
Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2024
WebIn our experience, FLAG-IDA is a well-tolerated and effective regimen in relapsed/refractory AML. The toxicity is acceptable, enabling most patients to receive further treatment, … WebWe studied the outcome of 47 adult patients with relapsed acute leukaemia (AML = 25 and ALL = 22) treated with FLAG-mitoxantrone regimen. Median time to relapse was 10.7 months (range 1.9-27.7). Complete remission (CR2) was 60.1% which was significantly more frequent in ALL compared to AML (P = 0.04 … cancerian horoscope
US Flag - Inspiration for Instruction
WebJun 27, 2024 · Several salvage protocols are used for re-induction therapy; however, none of these is considered as standard therapy. FLAG regimen as previously reported is a … WebConclusion: Our study confirmed that R3 block 1 is a highly active reinduction regimen in childhood relapsed ALL. However, it was associated with a high incidence of severe toxicities, particularly infection. The toxicity profiled in our report should be used to inform optimal supportive care and future clinical trial design with the R3 ... WebFLAG-Ida is a chemotherapy regimen widely used in patients with relapsed or refractory AML. It is often used in patients with refractory or relapsed AML who are awaiting an … cancer identification tests